Association of p21 3′ UTR gene polymorphism with cancer risk: Evidence from a meta-analysis

Jie Li, Zhenzhen Li, Quancheng Kan, Suke Sun, Yidong Li, Suyun WangScientific 2015 · DOI

Abstract

Numerous studies have investigated the risk of cancer associated with the polymorphism of p21 3' UTR (rs1059234 C > T), but results have been inconsistent. We performed this meta-analysis to drive a more precise estimation of the association between this polymorphism and risk of cancer. A comprehensive search was conducted to identify all case-control studies of the rs1059234 C > T polymorphism of p21 3' UTR and cancer susceptibility. A total of eleven eligible studies, including 3,099 cases and 4,354 controls, relating to the rs1059234 polymorphism of p21 3' UTR to the risk of cancer were identified. Multivariate and univariate methods revealed no association between this polymorphism and cancer risk. However, subgroup analysis by cancer type suggested that rs1059234 C > T polymorphism was associated with increased risk of squamous cell carcinoma of the head and neck (SCCHN) (dominant model CT + TT vs. CC: OR = 1.51, 95% CI = 1.17-1.94). No significant association was found in other subgroup analyses. This meta-analysis suggested that rs1059234 polymorphism of p21 3' UTR may be associated with increased SCCHN risk. And larger scale primary studies are required to further evaluate the interaction of p21 3' UTR rs1059234 polymorphism and cancer risk in specific populations.

Introduction

The p21 protein, encoded by the CDKN1A gene, acts as a molecular brake that halts the cell cycle to allow for DNA repair or to trigger programmed cell death (apoptosis). Because of this critical "gatekeeper" role, researchers have long investigated whether variations in the p21 gene influence cancer susceptibility. One specific single nucleotide polymorphism (SNP), rs1059234 (C>T), occurs in the 3′ Untranslated Region (UTR) of the gene. This region is vital for mRNA stability; changes here can lead to faster degradation of genetic instructions, potentially lowering p21 protein levels and allowing damaged cells to proliferate. While individual studies have yielded conflicting results, this meta-analysis pools data from multiple sources to provide a more statistically robust assessment of the association between this SNP and cancer risk.

Methods

The authors conducted a systematic review of literature up to September 2014, identifying 11 eligible case-control studies from databases such as PubMed, Medline, ISI Web of Knowledge, and Embase.

Flowchart of the literature search and study selection process.

Statistical modeling included both univariate and multivariate random-effects meta-analyses. The multivariate approach was particularly useful for modeling log-odds ratios of different genotypes simultaneously to infer the underlying genetic model. To account for potential variability, results were stratified by cancer type, ethnicity (Caucasian vs. Asian), source of controls, and study quality. Heterogeneity was measured using Cochran’s Q test and the $I^2$ statistic.

Datasets

The meta-analysis synthesized data from 11 previously published molecular epidemiological studies, representing a total sample size of 3,099 cancer cases and 4,354 healthy controls. The cancer types included in the analysis were prostate cancer, squamous cell carcinoma of the head and neck (SCCHN), colorectal cancer, and a group of "other" cancers (including esophageal, endometrial, and cervical). The demographic breakdown consisted of seven studies focused on Caucasian populations and four on Asian populations.

Key Results and Insights

General Cancer Risk

On a broad scale, the meta-analysis found that the rs1059234 polymorphism is not a universal predictor of cancer. When all 11 studies were pooled, the Odds Ratio (OR) for the dominant model was 1.07 (95% CI = 0.81–1.41), indicating no significant overall association.

Forest plot of cancer risk associated with the p21 rs1059234 polymorphism under the dominant model, stratified by ethnicity.

Tissue-Specific Susceptibility

The most significant finding was the discovery of tissue-specific risk. The T-allele was significantly associated with an increased risk of SCCHN, with carriers of the variant (CT or TT genotypes) having a 1.51 times higher risk compared to those with the standard CC genotype (OR = 1.51, 95% CI = 1.17–1.94). No significant association was found for prostate or colorectal cancers, suggesting that the impact of p21 regulation varies depending on the histological type of the tumor.

mRNA Stability Mechanism

These findings reinforce the theory that the 3' UTR is a critical regulatory site. Although this SNP does not change the protein's amino acid sequence, it likely alters the amount of protein available by affecting how long the mRNA survives in the cell. Sensitivity analyses confirmed that these results were stable and not driven by any single outlier study.

Limitations and Future Work

Several limitations prevent these findings from being definitive. The SCCHN subgroup analysis included only two studies, which is a small sample size for robust clinical conclusions. Furthermore, the meta-analysis could not account for gene-environment interactions, such as lifestyle factors like smoking or alcohol consumption. The authors also noted variability in control groups, with some studies using hospital-based rather than population-based controls. Future research should involve larger-scale primary studies that use standardized genotyping and account for complex gene-gene and gene-environment interactions to confirm the link between p21 polymorphisms and specific cancer risks.

Summary updated

Abstract

Numerous studies have investigated the risk of cancer associated with the polymorphism of p21 3' UTR (rs1059234 C > T), but results have been inconsistent. We performed this meta-analysis to drive a more precise estimation of the association between this polymorphism and risk of cancer. A comprehensive search was conducted to identify all case-control studies of the rs1059234 C > T polymorphism of p21 3' UTR and cancer susceptibility. A total of eleven eligible studies, including 3,099 cases and 4,354 controls, relating to the rs1059234 polymorphism of p21 3' UTR to the risk of cancer were identified. Multivariate and univariate methods revealed no association between this polymorphism and cancer risk. However, subgroup analysis by cancer type suggested that rs1059234 C > T polymorphism was associated with increased risk of squamous cell carcinoma of the head and neck (SCCHN) (dominant model CT + TT vs. CC: OR = 1.51, 95% CI = 1.17-1.94). No significant association was found in other subgroup analyses. This meta-analysis suggested that rs1059234 polymorphism of p21 3' UTR may be associated with increased SCCHN risk. And larger scale primary studies are required to further evaluate the interaction of p21 3' UTR rs1059234 polymorphism and cancer risk in specific populations.
BibTeX
@inproceedings{li2015association,
  author = {Jie Li and Zhenzhen Li and Quancheng Kan and Suke Sun and Yidong Li and Suyun Wang},
  title = {{Association of p21 3′ UTR gene polymorphism with cancer risk: Evidence from a meta-analysis}},
  booktitle = {Scientific},
  year = {2015},
  doi = {10.1038/srep13189},
}
Figure